Managed Care
Disease
Management

Treatment Persistence & Health Care Costs of Adult MDD Patients Treated With Escitalopram Vs. Citalopram in a Medicaid Population

MANAGED CARE January 2012. © MediMedia USA
Peer-Reviewed

Treatment Persistence & Health Care Costs of Adult MDD Patients Treated With Escitalopram Vs. Citalopram in a Medicaid Population

Escitalopram patients in a Florida Medicaid population had better treatment persistence and lower total health care costs than patients prescribed citalopram
Eric Q. Wu, PhD
Managing principal, the Analysis Group, Inc.
Rym Ben-Hamadi, MSc
Manager, the Analysis Group, Inc.
Mei Lu, MS
Associate, the Analysis Group, Inc.
Nicolas Beaulieu, MA
Associate, the Analysis Group, Inc.
Andrew P. Yu, PhD
Manager, the Analysis Group, Inc.
M. Haim Erder, PhD
Vice president for health economics and outcomes, Forest Research Institute
MANAGED CARE January 2012. ©MediMedia USA

Escitalopram patients in a Florida Medicaid population had better treatment persistence and lower total health care costs than patients prescribed citalopram

Eric Q. Wu, PhD

Managing principal, the Analysis Group, Inc.

Rym Ben-Hamadi, MSc

Manager, the Analysis Group, Inc.

Mei Lu, MS

Associate, the Analysis Group, Inc.

Nicolas Beaulieu, MA

Associate, the Analysis Group, Inc.

Andrew P. Yu, PhD

Manager, the Analysis Group, Inc.

M. Haim Erder, PhD

Vice president for health economics and outcomes, Forest Research Institute

Abstract

Objective: Compare treatment persistence and health care costs of major depressive disorder (MDD) Medicaid patients treated with escitalopram versus citalopram.

Design: Retrospective analysis of Medicaid administrative claims data.

Methodology: Analyzed administrative claims data from the Florida Medicaid program (07/2002–06/2006) for patients ages 18–64 years with ≥1 inpatient claim or 2 independent medical claims for MDD. Outcomes included discontinuation and switching rates and prescription drug, medical, and total health care costs, all-cause and related to mental disorder. Contingency table analysis and survival analysis were used to compare outcomes between treatment groups, using both unadjusted analysis and multivariate analysis adjusting for baseline characteristics.

Results: The study included 2,650 patients initiated on escitalopram and 630 patients initiated on citalopram. Patients treated with escitalopram were less likely to discontinue the index drug (63.7% vs. 68.9%, P=0.015) or to switch to another second-generation antidepressant (14.9% vs. 18.4%, P=0.029) over the six months post-index date. Patients treated with escitalopram had $1,014 lower total health care costs (P=0.032) and $519 lower health care costs related to mental disorder (P=0.023). More than half of the total cost difference was attributable to savings in inpatient hospitalizations related to mental disorder ($571, P=0.003) and to outpatient costs ($53, P<0.001). Escitalopram therapy was also associated with $736 lower medical costs related to mental disorder (P=0.009).

Conclusion: In the Florida Medicaid program, compared to adult MDD patients initiated on citalopram, escitalopram patients have better treatment persistence and lower total health care costs due to any cause and due to mental disorder, mostly driven by lower hospitalization costs related to mental disorder.